DFO
ASND icon

Duquesne Family Office’s Ascendis Pharma A/S ASND Stock Holding History

Duquesne Family Office’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-158,720
Closed -$24.7M – 73
2025
Q1 		$24.7M Sell
158,720
-106,320
-40% -$15.2M 0.81% 32
2024
Q4 		$36.5M Hold
265,040
– – 0.98% 30
2024
Q3 		$39.6M Buy
+265,040
New +$35.8M 1.34% 17

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Duquesne Family Office's ASND Position: Q2 2025 in Review

Duquesne Family Office sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 158,720 shares — an estimated $24.7M sold.

Duquesne Family Office first reported a position in ASND in Q3 2024 and held it in 3 quarters. The position peaked at $39.6M in Q3 2024. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

  • Duquesne Family Office reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
  • Duquesne Family Office sold 158,720 Ascendis Pharma A/S shares in Q2 2025, an estimated $24.7M.
  • Duquesne Family Office first reported a position in Ascendis Pharma A/S in Q3 2024 and held it in 3 quarters.
  • Duquesne Family Office's Ascendis Pharma A/S position peaked at $39.6M in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Duquesne Family Office's 13F filing for Q2 2025, filed 15 Aug 2025.